Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 19 July 2018, 06:00 HKT/SGT
Share:
    

Source: Novotech
Novotech Partners with Asian Eye Institute for Accelerated Ophthalmic Drug and Devices Clinical Trials

SYDNEY, July 19, 2018 - (ACN Newswire) - Asia-Pacific specialist CRO Novotech announced today it has partnered with the Asian Eye Institute, Inc (AEI), a private eye center in the Philippines, to facilitate high-quality and rapid feasibility, start-up and recruitment processes for its ophthalmology clients.

The AEI has conducted over 100 clinical trials and investigator-led research and has become one of the leading sites in Asia for research in ophthalmic drug and devices.

Under the terms of the MOU, the AEI will provide its professional and clinical trial expertise to Novotech managed studies including feasibility, principal investigator selection, patient recruitment and execution of ophthalmology studies.

Novotech works in partnership with leading medical institutions across Asia to accelerate quality clinical research. The AEI partnership is designed to give Novotech clients faster start-up times and access to the AEI patient database, and leading principal investigators.

The AEI treats 60,000 patients each year at clinics across the Philippines. Specialist services include:
- general ophthalmology
- conventional and Victus Femtolaser cataract surgery
- pediatric ophthalmology
- orthoptics
- adult and pediatric strabismus management
- glaucoma, vitreous, and retinal disease management
- corneal and external eye diseases
- refractive correction

In addition, the AEI:
-- Ethics Review Board holds a level 3 accreditation from the Philippine Health Research Ethics Board
-- has certification for ISO 9001:2008, 14001:2004 and OHSAS 18001:2007
-- is accredited by the Accreditation Canada International
-- is recognized member of the ASEAN Association of Eye Hospital (AAEH) and World Association of Eye Hospitals (WAEH).
-- is the only WAEH member in the Philippines
-- browse www.asianeyeinstitute.com

Novotech Executive Director, Asia Operations Dr. Yooni Kim said the Philippines with a population of 107 million is well established as a premier clinical research location.

"The MOU means Novotech will also have dedicated clinical experts within the AEI to support and prioritise rapid clinical processes for Novotech biopharma clients," Dr. Kim said.

"Novotech is the Asia-Pacific CRO, so is committed to establishing ongoing engagement with leading medical institutions in each country across the Asia-Pacific region. We have offices and teams on the ground as well as MOUs and long-term relationships with major hospitals that directly benefit our clients."

"Our in-country relationships enable a more comprehensive understanding of local regulatory changes, access to leading PIs, strong site connections, and productive patient populations to deliver success for our clients within timelines and budgets."

Novotech was established in 1996, headquartered in Australia with offices in 11 countries across the region, and MOUs with major health providers.

About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.

For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0

Media Contact
Susan Fitzpatrick-Napier
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427


July 19, 2018 06:00 HKT/SGT
Topic: Clinical Trial Results
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Multimedia
Mr. Benjamin K. Liboro, President of Asian Eye Institute, Inc. (left) and Dr Yooni Kim, Executive Director, Asia Operations Novotech
View Image
 

Novotech
Nov 28, 2018 11:02 HKT/SGT
Novotech CRO Announces 41 Clinical Staff and 81 Projects in South Korea
Oct 19, 2018 07:00 HKT/SGT
Novotech and CNS deal expands CRO services for Biopharma Clients across Asia-Pacific
Aug 23, 2018 13:00 HKT/SGT
Novotech the Asia-Pacific CRO named Top 10 CRO
Aug 9, 2018 13:00 HKT/SGT
Sponsors Recommend Novotech for CRO Leadership Award
June 28, 2018 06:00 HKT/SGT
Novotech at DIA18 announces Asia Partnerships on Target to Reach 1.4 Bil Patients
June 15, 2018 16:30 HKT/SGT
Novotech signs MoU with CMUH Taiwan to offer Enhanced Services for Global Trials
June 12, 2018 11:00 HKT/SGT
Novotech Signs MOU with China Medical University Hospital in Taiwan to Offer Enhanced Services for Global Trials
May 18, 2018 02:00 HKT/SGT
Novotech says Federal Budget R&D Tax Support Keeps Australia Globally Competitive for Quality Clinical Trials
June 23, 2017 08:00 HKT/SGT
Novotech signs Central Lab Services Agreement with Sonic Clinical Trials
Apr 18, 2017 10:00 HKT/SGT
Novotech signs MOU with South Korea's leading medical center, the Asan Medical Center
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: